The latest trading session saw Organon (OGN) ending at $15.06, denoting a +0.74% adjustment from its last day's close. The stock outpaced the S&P 500's daily loss of 1.11%. Elsewhere, the Dow lost 0.77%, while the tech-heavy Nasdaq lost 1.49%.The pharmaceutical company's shares have seen a decrease of 6.45% over the last month, not keeping up with the Medical sector's loss of 4.56% and the S&P 500's gain of 0.4%.Market participants will be closely following the financial results of Organon in its upcoming r ...

iREIT+HOYA Capital is the premier income-focused investing service on Seeking Alpha. Our focus is on income-producing asset classes that offer the opportunity for sustainable portfolio income , diversification , and inflation hedging . Get started with a Free Two-Week Trial and take a look at our top ideas across our exclusive income-focused portfolios. It pays to be patient when it comes to value stocks, especially when the market pendulum swings back and forth within the span of a year. While the overall ...

Analyst’s Disclosure: I/we have a beneficial long position in the shares of ABBV, MRK, AMGN, JNJ, RHHBF either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Additional disclosure: I may initiate a beneficial Long position through a purchase of the stock of Organon & Co. over ...

Table of Contents Large accelerated filer ☒ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ Form 10-Q ________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For ...

Organon Third Quarter 2024 Earnings ANON™ Disclaimer statement Cautionary Note Regarding Forward-Looking Statements Except for historical information, this presentation includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about management's expectations about Organon's future financial performance and prospects, including full-year 2024 guidance estimates and predictions ...

Financial Data and Key Metrics Changes - For Q3 2024, revenue was $1.6 billion, reflecting a 5% growth rate at constant currency [5] - Adjusted EBITDA was $459 million, representing a 29% adjusted EBITDA margin [5] - Year-to-date free cash flow generated was nearly $700 million, with a target of approximately $1 billion for 2024 [6][8] - Adjusted net income was $226 million or $0.87 per diluted share, nearly equal to the previous year's $223 million [27] Business Line Data and Key Metrics Changes - Women's health franchise grew 6%, driven by an 11% increase in Nexplanon [5][18] - Biosimilars franchise grew 17%, with expectations for low teens growth for the full year 2024 [20] - Established brands grew 3% in Q3, with expectations for flat to slightly better performance for the full year [21] Market Data and Key Metrics Changes - Nexplanon in the US grew 18% in Q3, with strong demand and pricing strategies contributing to growth [18] - The biosimilars market is expected to see continued uptake of Hadlima in the US, contributing to growth [20] - The established brands segment is facing challenges from the loss of exclusivity of Atozet and pricing revisions in Japan [21][31] Company Strategy and Development Direction - The acquisition of Dermavant and its key asset VTAMA is seen as a strategic move to address the atopic dermatitis market, which has significant unmet needs [9][15] - The company plans to leverage its existing dermatology expertise and expand its presence in the US market [16] - Future growth is expected to be supported by organic growth drivers and contributions from recent business developments [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving $1 billion in revenue for Nexplanon next year, indicating strong market positioning [40] - The company anticipates continued revenue growth in 2025, driven by organic growth and contributions from the Dermavant acquisition [8][35] - Management acknowledged challenges from pricing pressures and competitive dynamics in the market but remains optimistic about long-term growth prospects [31] Other Important Information - The company revised its full-year 2024 adjusted EBITDA margin range to 30% to 31% [8] - The impact of foreign exchange translation was approximately $20 million, reflecting a stronger US dollar [25] - The company expects to achieve at least $150 million in sales of VTAMA in 2025, with potential growth to $0.5 billion over the next three to five years [15] Q&A Session Summary Question: Current profitability or EBITDA contribution from Dermavant - Management indicated a revenue run rate of approximately $6 million per month for VTAMA, with similar levels of dilution expected for 2024 [39] Question: Current political climate regarding LARCs and Nexplanon growth drivers - Management noted strong bipartisan support for access to contraception and expressed confidence in Nexplanon's growth trajectory [40] Question: Leveraging medical derm commercial infrastructure for future acquisitions - Management expressed enthusiasm for the opportunities presented by the Dermavant acquisition and indicated plans to explore additional assets in the dermatology space [42] Question: Incremental selling and marketing costs for Dermavant - Management clarified that the $180 million OpEx for 2025 includes onboarding costs for sales and marketing capabilities, with a focus on successful product launch [45] Question: Ex-US spend included in the $180 million OpEx - Management confirmed that the $180 million OpEx is primarily US-focused, with minimal significant spending planned outside the US [49]

For the quarter ended September 2024, Organon (OGN) reported revenue of $1.58 billion, up 4.2% over the same period last year. EPS came in at $0.87, compared to $0.87 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $1.56 billion, representing a surprise of +1.37%. The company delivered an EPS surprise of +2.35%, with the consensus EPS estimate being $0.85.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they ...

Organon (OGN) came out with quarterly earnings of $0.87 per share, beating the Zacks Consensus Estimate of $0.85 per share. This compares to earnings of $0.87 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 2.35%. A quarter ago, it was expected that this pharmaceutical company would post earnings of $1.06 per share when it actually produced earnings of $1.12, delivering a surprise of 5.66%.Over the last four quarters, the comp ...

Exhibit 99.1 | --- | --- | --- | --- | |-------------------|----------------------------------|----------------------|-----------------------------------| | | | | | | | | | | | Media Contacts: | Karissa Peer | Investor Contacts: | Jennifer Halchak | | | (614) 314-8094 Kate Vossen | | (201) 275-2711 Renee McKnight | | | (732) 675-8448 | | (551) 204-6129 | Organon Reports Results for the Third Quarter Ended September 30, 2024 · Third quarter 2024 revenue of $1.582 billion, up 4% as-reported and up 5% at const ...

The upcoming report from Organon (OGN) is expected to reveal quarterly earnings of $0.85 per share, indicating a decline of 2.3% compared to the year-ago period. Analysts forecast revenues of $1.56 billion, representing an increase of 2.7% year over year. The current level reflects an upward revision of 1.1% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period. Befor ...